Hot Investor Mandate: USA Arm of a Leading Asian VC Firm Invests Up to $20M, Most Interested in Clinical Stage Therapeutics in Immuno-oncology, Ophthalmology, and More

3 Feb

A wholly owned subsidiary of a leading venture capital firm headquartered in Asia was established to focus on US-based biotechnology companies. The firm is interested in opportunities at all stages of development and can allocate between $500 K up to $20 M in equity investments, acting as a lead or follow on.

The firm is currently focusing on the areas of immuno-oncology, gene therapy, ophthalmology, and platform technologies. Previous investments include companies targeting clinical stage small molecule therapeutics for oncology, cyclic peptide drugs for immuno-modulation in chronic inflammatory diseases, and delivery methods and therapeutics for blinding diseases of the eye. The firm invests only in therapeutics, and is very open to investing in early-stage, pre-clinical assets. The firm has been working with a large network of universities and tech transfers to identify promising early-stage opportunities.

The story behind the company and management team is important to the firm. The firm looks for a cohesive business plan and strategy, and are especially interested in opportunities with potential to expand into the Asian market. The firm has a strong network of pharmaceuticals and investors in South Korea that can support market entry. The firm is open to both leading and co-investing, and seeks board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: